Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27932397 | 0.98 | TAAR1 (0.34) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL9330630 | 0.98 | TAAR1 (0.34) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL27501269 | 0.87 | ALDH1A1 (0.37) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL3603367 | 0.83 | TAAR1 (0.33) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL2651837 | 0.83 | TRPA1 (0.36) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL3616684 | 0.83 | TAAR1 (0.33) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL3608914 | 0.83 | TAAR1 (0.33) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL3016224 | 0.82 | SIGMAR1 (0.45) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL1071752 | 0.82 | TRPA1 (0.35) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL4967174 | 0.80 | MAOB (0.34) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 793 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | claimed |
| WO-2024126475-A1 | PROCESS FOR THE PRODUCTION OF AN ALKYLSTYRENE AND OF AN ALKYLPHENYL PROPIONIC ACID | BASF SE (DE) | 2024-06-20 | — | — | WO | claimed |
| EP-4134362-B1 | IBUPROFEN ESTER DERIVATIVE AND EMULSION FORMULATION THEREOF | NANJING HERON PHARMACEUTICAL SCIENCE AND TECH CO LTD (CN) | 2024-02-28 | — | — | EP | claimed |
| WO-2023196594-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2021113498-A1 | CYCLOOXYGENASE-2 INHIBITION FOR THE TREATMENT OF SAA-HIGH ASTHMA | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-10 | — | — | WO | claimed |
| CN-106232120-B | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2- (1H) -ones | 爱尔皮奥治疗有限公司 | 2021-01-08 | — | — | CN | claimed |
| CN-104447495-B | Chiral beta replaces α, the preparation method of β unsaturated amino alcohols class compounds | 上海交通大学 | 2017-08-01 | — | — | CN | claimed |
| US-9388135-B2 | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones | AERPIO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | claimed |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. | 2015-08-20 | — | — | US | claimed |
| US-8344142-B2 | perylenetetracarboxylic diimide core having side chains (groups or mesogens) attached to the core; to provide charge-transport materials having various volatilities, solubilities, crystallinity, and charge transport ability; organic light emitting diode; photovoltaic cells, light-emitting diodes | GEORGIA TECH RESEARCH CORPORATION (US) | 2013-01-01 | — | — | US | claimed |
| WO-1998025918-A1 | ANALGESIC, ANTI-INFLAMMATORY AND ANTI-THROMBOSIS ESTERS OF NITRATED CYCLOALIPHATIC ALCOHOLS | HOECHST MARION ROUSSEL (FR) | 1998-06-18 | — | — | WO | claimed |
| EP-0623104-B1 | PROFEN RESOLUTION | ALBEMARLE CORP (US) | 1997-08-27 | — | — | EP | claimed |
| CN-1132756-A | Antiviral ethers of aspartate protease substrate isosteres | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | claimed |
| CN-1025609-C | Process for purifying 2-(4-isobutylphenyl)-propionic acid | HOECHST AG (US) | 1994-08-10 | — | — | CN | claimed |
| US-5206149-A | Reaction of peroxidase, oxidant, luminol and 2-hydroxy-9-fluorenone enhancer; chemiluminescence | TORAY INDUSTRIES, INC. (JP) | 1993-04-27 | — | — | US | claimed |
| US-5198568-A | Improved resolution of enantiomorphs by forming water soluble derivatives, ibuprofen derivatives | SEPRACOR, INC. (US) | 1993-03-30 | — | — | US | claimed |
| EP-0423133-A4 | ENZYMATIC RESOLUTION SYSTEMS AND COMPOUNDS USEFUL IN THE SYSTEMS AND THEIR REPARATIONS | — | 1992-04-15 | — | — | EP | claimed |
| EP-0423133-A1 | ENZYMATIC RESOLUTION SYSTEMS AND COMPOUNDS USEFUL IN THE SYSTEMS AND THEIR REPARATIONS. | SEPRACOR INC (US) | 1991-04-24 | — | — | EP | claimed |
| WO-1989009765-A1 | ENZYMATIC RESOLUTION SYSTEMS AND COMPOUNDS USEFUL IN THE SYSTEMS AND THEIR REPARATIONS | SEPRACOR, INC. (US) | 1989-10-19 | — | — | WO | claimed |
| CN-1035821-A | The method of purification of 2-(4-isobutylphenyl)-propionic acid | HOECHST AG (DE) | 1989-09-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | TAAR1 916/4885SLC6A2 188/4885SLC6A4 956/4885 |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | CYP4B1, CYP8B1, HPD | TAAR1 3279/4885SLC6A2 3816/4885SLC6A4 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.